1 Ocak 2020 Dergi makalesi Açık Erişim

Reeder, Sophia M.; Reuschel, Emma L.; Bah, Mamadou A.; Yun, Kun; Tursi, Nicholas J.; Kim, Kevin Y.; Chu, Jacqueline; Zaidi, Faraz, I; Yilmaz, Ilknur; Hart, Robert J.; Perrin, Benjamin; Xu, Ziyang; Humeau, Laurent; Weiner, David B.; Aly, Ahmed S., I

JSON

{
  "conceptrecid": "10304", 
  "created": "2021-03-15T07:25:01.843712+00:00", 
  "doi": "10.3390/vaccines8010021", 
  "files": [
    {
      "bucket": "e2e3d469-460d-427d-8346-4ad7a52734a1", 
      "checksum": "md5:c628bc398cb8f62afed821ffd99525e1", 
      "key": "bib-3bb959c7-3123-4db1-9158-2bf0136cfb96.txt", 
      "links": {
        "self": "https://aperta.ulakbim.gov.tr/api/files/e2e3d469-460d-427d-8346-4ad7a52734a1/bib-3bb959c7-3123-4db1-9158-2bf0136cfb96.txt"
      }, 
      "size": 325, 
      "type": "txt"
    }
  ], 
  "id": 10305, 
  "links": {
    "badge": "https://aperta.ulakbim.gov.tr/badge/doi/10.3390/vaccines8010021.svg", 
    "bucket": "https://aperta.ulakbim.gov.tr/api/files/e2e3d469-460d-427d-8346-4ad7a52734a1", 
    "doi": "https://doi.org/10.3390/vaccines8010021", 
    "html": "https://aperta.ulakbim.gov.tr/record/10305", 
    "latest": "https://aperta.ulakbim.gov.tr/api/records/10305", 
    "latest_html": "https://aperta.ulakbim.gov.tr/record/10305"
  }, 
  "metadata": {
    "access_right": "open", 
    "access_right_category": "success", 
    "communities": [
      {
        "id": "tubitak-destekli-proje-yayinlari"
      }
    ], 
    "creators": [
      {
        "name": "Reeder, Sophia M."
      }, 
      {
        "affiliation": "Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA", 
        "name": "Reuschel, Emma L."
      }, 
      {
        "affiliation": "Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA", 
        "name": "Bah, Mamadou A."
      }, 
      {
        "name": "Yun, Kun"
      }, 
      {
        "affiliation": "Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA", 
        "name": "Tursi, Nicholas J."
      }, 
      {
        "affiliation": "Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA", 
        "name": "Kim, Kevin Y."
      }, 
      {
        "affiliation": "Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA", 
        "name": "Chu, Jacqueline"
      }, 
      {
        "affiliation": "Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA", 
        "name": "Zaidi, Faraz, I"
      }, 
      {
        "affiliation": "Bezmialem Vakif Univ, Beykoz Inst Life Sci & Biotechnol, Istanbul 34820, Turkey", 
        "name": "Yilmaz, Ilknur"
      }, 
      {
        "affiliation": "Tulane Univ, Dept Trop Med, New Orleans, LA 70112 USA", 
        "name": "Hart, Robert J."
      }, 
      {
        "affiliation": "Tulane Univ, Dept Trop Med, New Orleans, LA 70112 USA", 
        "name": "Perrin, Benjamin"
      }, 
      {
        "name": "Xu, Ziyang"
      }, 
      {
        "affiliation": "Inovio Pharmaceut Inc, Plymouth Meeting, PA 19462 USA", 
        "name": "Humeau, Laurent"
      }, 
      {
        "affiliation": "Vaccine Ctr, Wistar Inst, Philadelphia, PA 19104 USA", 
        "name": "Weiner, David B."
      }, 
      {
        "name": "Aly, Ahmed S., I"
      }
    ], 
    "description": "The need for a malaria vaccine is indisputable. A single vaccine for Plasmodium pre-erythrocytic stages targeting the major sporozoite antigen circumsporozoite protein (CSP) has had partial success. Additionally, CD8+ T cells targeting liver-stage (LS) antigens induced by live attenuated sporozoite vaccines were associated with protection in human challenge experiments. To further evaluate protection mediated by LS antigens, we focused on exported pre-erythrocytic proteins (exported protein 1 (EXP1), profilin (PFN), exported protein 2 (EXP2), inhibitor of cysteine proteases (ICP), transmembrane protein 21 (TMP21), and upregulated in infective sporozoites-3 (UIS3)) expressed in all Plasmodium species and designed optimized, synthetic DNA (synDNA) immunogens. SynDNA antigen cocktails were tested with and without the molecular adjuvant plasmid IL-33. Immunized animals developed robust T cell responses including induction of antigen-specific liver-localized CD8+ T cells, which were enhanced by the co-delivery of plasmid IL-33. In total, 100% of mice in adjuvanted groups and 71%-88% in non-adjuvanted groups were protected from blood-stage disease following Plasmodium yoelii sporozoite challenge. This study supports the potential of synDNA LS antigens as vaccine components for malaria parasite infection.", 
    "doi": "10.3390/vaccines8010021", 
    "has_grant": false, 
    "journal": {
      "issue": "1", 
      "title": "VACCINES", 
      "volume": "8"
    }, 
    "license": {
      "id": "cc-by"
    }, 
    "publication_date": "2020-01-01", 
    "relations": {
      "version": [
        {
          "count": 1, 
          "index": 0, 
          "is_last": true, 
          "last_child": {
            "pid_type": "recid", 
            "pid_value": "10305"
          }, 
          "parent": {
            "pid_type": "recid", 
            "pid_value": "10304"
          }
        }
      ]
    }, 
    "resource_type": {
      "subtype": "article", 
      "title": "Dergi makalesi", 
      "type": "publication"
    }, 
    "title": "Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model"
  }, 
  "owners": [
    1
  ], 
  "revision": 1, 
  "stats": {
    "downloads": 5.0, 
    "unique_downloads": 5.0, 
    "unique_views": 44.0, 
    "version_downloads": 5.0, 
    "version_unique_downloads": 5.0, 
    "version_unique_views": 44.0, 
    "version_views": 46.0, 
    "version_volume": 1625.0, 
    "views": 46.0, 
    "volume": 1625.0
  }, 
  "updated": "2021-03-15T07:25:01.890283+00:00"
}